文献速递慢性肾脏病水电解质与酸碱

低剂量二甲双胍在4期糖尿病肾病中的药代动力学研究

Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy.
PubMed 文献 · Kidney Int Rep · 2017-03-29

这项开放标签I期试验在4期慢性肾脏病合并2型糖尿病患者中,评估每日一次250、500或1000mg二甲双胍的药代动力学、安全性和有效性。结果显示4周治疗无药物蓄积,无高乳酸血症或代谢性酸中毒,血糖和HbA1c均下降。研究支持在该人群中放宽二甲双胍使用,并支持用药物浓度检测个体化给药。

要点

  • 4期糖尿病肾病患者使用低剂量二甲双胍4周未出现药物蓄积。
  • 未发生高乳酸血症或代谢性酸中毒,生化安全指标无显著变化。
  • 各队列血糖和HbA1c均下降,支持个体化给药监测。

核心结论

  • 4期慢性肾脏病合并2型糖尿病患者接受4周低剂量二甲双胍治疗未出现不良安全结局,药代动力学稳定。

研究设计与样本

  • 开放标签I期试验,连续3个队列各6例患者,分别接受每日一次250、500或1000mg二甲双胍,治疗4周。

主要发现

  • 任何队列均无二甲双胍蓄积证据。
  • 无高乳酸血症或代谢性酸中毒事件,生化安全指标无显著变化。
  • 队列1、2、3的中位(四分位距)谷浓度为0.083(0.121)mg/l、0.239(0.603)mg/l和1.930(3.110)mg/l。
  • 所有队列平均毛细血管葡萄糖浓度和平均HbA1c均下降。

关键数值与推荐

  • 预设安全终点包括血清碳酸氢盐、静脉pH和血清乳酸,每周评估。
  • 疗效通过治疗前后HbA1c和72小时毛细血管葡萄糖监测评估。

临床怎么用

  • 研究支持在4期慢性肾脏病人群中放宽二甲双胍使用。
  • 支持使用二甲双胍浓度检测进行更个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metformin use in advanced chronic kidney disease is controversial. This study sought to examine the pharmacokinetics, safety, and efficacy of low-dose metformin in patients with type 2 diabetes and stage 4 chronic kidney disease. METHODS: In this open-label, phase I trial, 3 consecutive cohorts (1, 2, and 3) of 6 patients each were recruited to receive 250-, 500-, or 1000-mg once-daily doses of metformin, respectively. All patients underwent a first-dose pharmacokinetic profile and weekly trough metformin concentrations for the duration of 4 weeks of daily therapy. Prespecified clinical and biochemical safety endpoints of serum bicarbonate, venous pH, and serum lactate were assessed weekly. Efficacy was assessed by pre- and post-HbA1c and 72-hour capillary glucose monitoring. RESULTS: There was no evidence of accumulation of metformin in any cohort. There were no episodes of hyperlactatemia or metabolic acidosis and no significant change in any biochemical safety measures. Median (interquartile range) observed trough concentrations of metformin in cohorts 1, 2, and 3 were 0.083 (0.121) mg/l, 0.239 (0.603) mg/l, and 1.930 (3.110) mg/l, respectively. Average capillary glucose concentrations and mean HbA1c decreased in all cohorts. DISCUSSION: In our patient cohorts with diabetes and stage 4 chronic kidney disease, treatment with 4 weeks of low-dose metformin was not associated with adverse safety outcomes and revealed stable pharmacokinetics. Our study supports the liberalization of metformin use in this population and supports the use of metformin assays for more individualized dosing.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dissanayake AM, Wheldon MC, Ahmed J, et al. Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. Kidney Int Rep. 2017. PMID: 29318219. doi:10.1016/j.ekir.2017.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。